Covid-19: UK becomes first country to authorise antiviral molnupiravir
BMJ 2021; 375 doi: https://doi.org/10.1136/bmj.n2697 (Published 04 November 2021) Cite this as: BMJ 2021;375:n2697Read our latest coverage of the coronavirus pandemic
- Elisabeth Mahase
- The BMJ
The UK’s medicines regulator has issued temporary authorisation of the antiviral drug molnupiravir for the treatment of mild to moderate covid-19 in adults with at least one risk factor for severe illness.1
The Medicines and Healthcare Products Regulatory Agency is the first regulator in the world to approve the drug, of which the UK has ordered 480 000 courses.
Molnupiravir will be rolled out to the people most at risk of covid-19, with the aim of reducing symptom severity and easing pressure on the NHS over winter, the Department of Health and Social Care for England has said.2
Interim phase …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.